
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics is viewed positively because 3Q26 showed a clear operating beat, with total revenue of $202.7M, gross margin of 68.2%, and adjusted EBITDA of -$5.3M all outperforming expectations, while volume growth and improved ASP trends across CCC, HCT, and Mental Health signal healthier underlying demand. The company also raised FY26 revenue guidance to $780M-$790M and has $107.1M in cash plus about $182M of available capital, giving it flexibility to support growth and execution. Longer term, the planned Prenatal divestiture for $210M is expected to lift growth by more than 100 bps and gross margin by more than 500 bps, while ASCEND and reimbursement initiatives should improve profitability and cash generation.
Bears say
Myriad Genetics is facing a weak fundamental setup because competition is intense across prenatal, oncology, and mental health testing, while pricing pressure in mature hereditary cancer markets continues to erode average selling prices and limits organic growth. The company’s recent results underscore structural issues: revenue declined low double digits, margins compressed 460 bps year over year, prenatal revenue fell 16% to about $40 million, and guidance was cut by $90 million at the midpoint, suggesting demand and reimbursement challenges are not temporary. Although the Prenatal sale improves cash runway and may help margins, the business still lacks clear evidence that new products can offset share loss, stabilize pricing, and restore sustainable profitability.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Myriad Genetics (MYGN) Forecast
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares